Maria Karasarides

3.1k total citations · 1 hit paper
20 papers, 2.3k citations indexed

About

Maria Karasarides is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Maria Karasarides has authored 20 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Maria Karasarides's work include Melanoma and MAPK Pathways (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Protein Kinase Regulation and GTPase Signaling (4 papers). Maria Karasarides is often cited by papers focused on Melanoma and MAPK Pathways (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Protein Kinase Regulation and GTPase Signaling (4 papers). Maria Karasarides collaborates with scholars based in United States, United Kingdom and Spain. Maria Karasarides's co-authors include Richard Marais, Claudia Wellbrock, Christopher J. Marshall, Dan Niculescu‐Duvaz, Caroline J. Springer, Lesley Ogilvie, Jan Martin, Douglas Hedley, Robert Hayward and D. K. Bird and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Maria Karasarides

18 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The RAF proteins take centre stage

2004 920 citations Claudia Wellbrock, Maria Karasarides et al. Nature Reviews Molecular Cell Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maria Karasarides United States	12	1.8k	833	307	262	260	20	2.3k
Alastair J. King United States	18	1.6k 0.9×	659 0.8×	289 0.9×	182 0.7×	223 0.9×	28	2.0k
Narsis Attar United States	11	2.1k 1.2×	1.3k 1.6×	194 0.6×	298 1.1×	297 1.1×	13	2.6k
Jessie Villanueva United States	18	1.6k 0.9×	799 1.0×	314 1.0×	145 0.6×	282 1.1×	30	2.1k
Jiing‐Dwan Lee United States	21	2.1k 1.2×	472 0.6×	450 1.5×	157 0.6×	230 0.9×	26	2.7k
Jiancheng Hu China	19	1.4k 0.8×	390 0.5×	219 0.7×	252 1.0×	246 0.9×	51	2.0k
Paul Wan United Kingdom	9	1.9k 1.1×	991 1.2×	208 0.7×	425 1.6×	130 0.5×	9	2.5k
Ensar Halilovic United States	19	1.8k 1.0×	977 1.2×	373 1.2×	336 1.3×	128 0.5×	33	2.3k
Kathryn Balmanno United Kingdom	25	2.4k 1.3×	956 1.1×	309 1.0×	429 1.6×	397 1.5×	45	3.2k
Katherine G. Moss United States	15	1.2k 0.7×	666 0.8×	423 1.4×	189 0.7×	182 0.7×	17	1.9k
Annalisa Petrelli Italy	19	1.4k 0.8×	490 0.6×	322 1.0×	132 0.5×	175 0.7×	26	2.1k

Countries citing papers authored by Maria Karasarides

Since Specialization

Citations

This map shows the geographic impact of Maria Karasarides's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Karasarides with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Karasarides more than expected).

Fields of papers citing papers by Maria Karasarides

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Karasarides. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Karasarides. The network helps show where Maria Karasarides may publish in the future.

Co-authorship network of co-authors of Maria Karasarides

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Karasarides. A scholar is included among the top collaborators of Maria Karasarides based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Karasarides. Maria Karasarides is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pirhaji, Leila, et al.. (2025). mzLearn as a data-driven LC/MS signal detection algorithm that enables pre-trained generative models for untargeted metabolomics. Communications Chemistry. 8(1). 398–398.

Badve, Sunil, Tobias Lang, David S. Mulder, et al.. (2024). AI based PD-L1 CPS quantifier software to identify more patients for checkpoint therapy in gastric cancer at pathologist-level interobserver concordance.. Journal of Clinical Oncology. 42(16_suppl). 2633–2633. 2 indexed citations

Robert, Marie E., Josef Rüschoff, Bharat Jasani, et al.. (2023). High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma. Modern Pathology. 36(5). 100154–100154. 37 indexed citations

Pantel, Klaus, Claus L. Andersen, Ed Schuuring, et al.. (2023). 237TiP GUIDE.MRD: A Consortium guiding multi-modal therapies against minimal residual disease (MRD) by liquid biopsy to assess implementation of circulating tumor DNA (ctDNA) in clinical practice to improve patient outcomes. Annals of Oncology. 34. S276–S277. 5 indexed citations

Cooper, Dennis, Deepu Madduri, Suzanne Lentzsch, et al.. (2019). Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 134(Supplement_1). 3176–3176. 31 indexed citations

Papadopoulos, Kyriakos P., Nehal J. Lakhani, Melissa L. Johnson, et al.. (2019). First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.. Journal of Clinical Oncology. 37(15_suppl). 2508–2508. 30 indexed citations

Papadopoulos, Kyriakos P., Nehal J. Lakhani, Melissa L. Johnson, et al.. (2018). A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody, in advanced cancers.. Journal of Clinical Oncology. 36(15_suppl). TPS3127–TPS3127. 5 indexed citations

Golan, Talia, Chia‐Chi Lin, Siqing Fu, et al.. (2017). A multi-cohort phase 1 study of ramucirumab plus durvalumab: Preliminary safety and clinical activity in patients with locally advanced and unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology. 28. iii5–iii5. 5 indexed citations

Melisi, Davide, Susan C. Guba, Maria Karasarides, & Valérie André. (2017). Phase 1b dose-escalation and cohort-expansion study of the safety, tolerability, and efficacy of a novel transforming growth factor-β receptor I kinase inhibitor (galunisertib [G]) administered in combination with the anti-PD-L1 antibody (durvalumab [D]) in recurrent or refractory metastatic pancreatic cancer.. Journal of Clinical Oncology. 35(4_suppl). TPS501–TPS501. 3 indexed citations

10.

Bang, Yung‐Jue, Laura W. Goff, Jing Yang, et al.. (2016). An open-label, multicenter, phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC). Annals of Oncology. 27. vi376–vi376.

11.

Hübner, Anette, David J. Mulholland, Claire L. Standen, et al.. (2012). JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proceedings of the National Academy of Sciences. 109(30). 12046–12051. 74 indexed citations

12.

Heller, Kevin N., Anne C. Pavlick, F. Stephen Hodi, et al.. (2011). Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases.. Journal of Clinical Oncology. 29(15_suppl). 8581–8581. 29 indexed citations

13.

Gray‐Schopfer, Vanessa C., Maria Karasarides, Robert Hayward, & Richard Marais. (2007). Tumor Necrosis Factor-α Blocks Apoptosis in Melanoma Cells when BRAF Signaling Is Inhibited. Cancer Research. 67(1). 122–129. 96 indexed citations

14.

Jaeschke, Anja, Maria Karasarides, Juan‐José Ventura, et al.. (2006). JNK2 Is a Positive Regulator of the cJun Transcription Factor. Molecular Cell. 23(6). 899–911. 134 indexed citations

15.

Mavria, Georgia, Yvonne Vercoulen, Maggie Yeo, et al.. (2006). ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Cancer Cell. 9(1). 33–44. 268 indexed citations

16.

Karasarides, Maria, et al.. (2006). Active Ras‐induced effects on skeletal myoblast differentiation and apoptosis are independent of constitutive PI3‐kinase activity. Cell Biology International. 30(4). 308–318. 9 indexed citations

17.

Karasarides, Maria, Antonio Chiloeches, Robert Hayward, et al.. (2004). B-RAF is a therapeutic target in melanoma. Oncogene. 23(37). 6292–6298. 360 indexed citations

18.

Wellbrock, Claudia, Maria Karasarides, & Richard Marais. (2004). The RAF proteins take centre stage. Nature Reviews Molecular Cell Biology. 5(11). 875–885. 920 indexed citations breakdown →

19.

Wellbrock, Claudia, Lesley Ogilvie, Douglas Hedley, et al.. (2004). V599EB-RAF is an Oncogene in Melanocytes. Cancer Research. 64(7). 2338–2342. 271 indexed citations

20.

Karasarides, Maria, Bela Anand‐Apte, & Alan Wolfman. (2001). A Direct Interaction between Oncogenic Ha-Ras and Phosphatidylinositol 3-Kinase Is Not Required for Ha-Ras-dependent Transformation of Epithelial Cells. Journal of Biological Chemistry. 276(43). 39755–39764. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact